CMS Francis Lefebvre has advised Eye Tech Care (hereinafter “ETC”) in the context of (i) an equity investment and an acquisition of shares by the China Medical System group, through certain subsidiaries of the group, of approximately 33.4 % of the share capital of ETC and (ii) the conclusion of a license, collaboration and distribution agreement with the companies of the China Medical System group concerning the EyeOP1® ultrasound glaucoma treatment device.
Jeantet has advised the China Medical System group in this transaction.
The new investment by the China Medial System group will give ETC a strong impetus for its international growth.
Founded in 2008 in Lyon (France) by experts in the field of therapeutic ultrasound and in partnership with INSERM, ETC is dedicated to the application of therapeutic ultrasound technology in the fight against glaucoma, by developing and promoting the EyeOP1® glaucoma treatment device for the non-invasive UCP® treatment of this ophthalmologic disease.
The CMS Francis Lefebvre team was composed of Xinyu Hu and David Mantienne, counsels, and Yanchao Wu, associate, in Corporate/ M&A, Johann Roc’h and Henri Bitar, partners, in Tax Law, and Nicolas Zhu, partner, and Laila Lu, associate, from CMS Shanghai, in the Commercial Contracts Law.
The China Medical System group was advised by Jeantet, with a team composed of Thierry Brun, partner, Maxime Brotz, counsel, Pak-Hang Li, You Shang and Maria Plakci, associates, in Corporate/M&A.
